Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report)‘s stock had its “market outperform” rating reaffirmed by equities ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) has been given an average rating of “Moderate Buy” by the thirteen ratings firms that are presently covering the stock, Marketbeat.com ...

Bank of America Securities analyst Jason Zemansky maintained a Sell rating on Madrigal Pharmaceuticals (MDGL – Research Report) today and set a ...

Competitors with MASH therapies like NVO, SGMT, ALT and Boehringer Ingelheim are making progress, although the possibility of combinations could limit any downside for MDGL. There is ongoing ...

Below is Validea's guru fundamental report for MADRIGAL PHARMACEUTICALS INC (MDGL). Of the 22 guru strategies we follow, MDGL rates highest using our Contrarian Investor model based on the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

CONSHOHOCKEN, Pa., Jan. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MDGL) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 ...

CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor ...

Short interest is currently not available. Nasdaq provides information of company’s short interest and the average days it takes to cover them. Short interest and days to cover can be used to ...